Equillium, Inc. (EQ) analyst actions
Rating and price-target actions on EQ in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the EQ overview →
1 measured EQ analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Equillium Maintains Rights to Itolizumab Following Ono Partnership | Press release | -12.16% | -22.43% |
Keep exploring
More EQ: earnings → · SEC filings → · EQ overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | 235 | -0.68% | 37% |
| Rockwell Medical, Inc. (RMTI) | 235 | +0.40% | 57% |
| Eton Pharmaceuticals, Inc. (ETON) | 234 | -0.34% | 40% |
| THERAPIX BIOSCIENCES LTD AMERICAN DEPOSITARY SHARE (TRPX) | 234 | -1.05% | 31% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.